铜绿假单胞菌中苯唑西林酶介导的对头孢吡肟耐药及对头孢他啶敏感
Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.
作者信息
Aubert D, Poirel L, Chevalier J, Leotard S, Pages J M, Nordmann P
机构信息
Service de Bactériologie-Virologie, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine Paris-Sud, 94275 Le Kremlin-Bicêtre, France.
出版信息
Antimicrob Agents Chemother. 2001 Jun;45(6):1615-20. doi: 10.1128/AAC.45.6.1615-1620.2001.
Abstract
Pseudomonas aeruginosa clinical isolate SOF-1 was resistant to cefepime and susceptible to ceftazidime. This resistance phenotype was explained by the expression of OXA-31, which shared 98% amino acid identity with a class D beta-lactamase, OXA-1. The oxa-31 gene was located on a ca. 300-kb nonconjugative plasmid and on a class 1 integron. No additional efflux mechanism for cefepime was detected in P. aeruginosa SOF-1. Resistance to cefepime and susceptibility to ceftazidime in P. aeruginosa were conferred by OXA-1 as well.
摘要
铜绿假单胞菌临床分离株SOF-1对头孢吡肟耐药，对头孢他啶敏感。这种耐药表型可通过OXA-31的表达来解释，OXA-31与D类β-内酰胺酶OXA-1的氨基酸同一性为98%。oxa-31基因位于一个约300kb的非接合性质粒和一个1类整合子上。在铜绿假单胞菌SOF-1中未检测到针对头孢吡肟的其他外排机制。铜绿假单胞菌对头孢吡肟的耐药性和对头孢他啶的敏感性也由OXA-1介导。
相似文献
1
Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2001 Jun;45(6):1615-20. doi: 10.1128/AAC.45.6.1615-1620.2001.
2
In vivo selection of oxacillinase-mediated ceftazidime resistance in Pseudomonas aeruginosa.
Microb Drug Resist. 2001 Fall;7(3):273-5. doi: 10.1089/10766290152652828.
3
Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother. 1992 Nov;30(5):633-41. doi: 10.1093/jac/30.5.633.
4
Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
Clin Microbiol Infect. 2011 Dec;17(12):1817-22. doi: 10.1111/j.1469-0691.2011.03530.x. Epub 2011 May 23.
5
Nosocomial spread of the integron-located veb-1-like cassette encoding an extended-pectrum beta-lactamase in Pseudomonas aeruginosa in Thailand.
Clin Infect Dis. 2002 Mar 1;34(5):603-11. doi: 10.1086/338786. Epub 2002 Jan 23.
6
Integron-located oxa-32 gene cassette encoding an extended-spectrum variant of OXA-2 beta-lactamase from Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2002 Feb;46(2):566-9. doi: 10.1128/AAC.46.2.566-569.2002.
7
Distribution of Ambler class A, B and D β-lactamases among Pseudomonas aeruginosa isolates.
Burns. 2012 Sep;38(6):855-60. doi: 10.1016/j.burns.2012.01.005. Epub 2012 Feb 19.
8
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.01110-19. Print 2019 Oct.
9
Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
Antimicrob Agents Chemother. 2010 Oct;54(10):4092-7. doi: 10.1128/AAC.00060-10. Epub 2010 Jul 6.
10
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01117-17. Print 2017 Sep.
引用本文的文献
1
Involvement of the gene in emergence of a peculiar resistance phenotype in .
Front Cell Infect Microbiol. 2025 May 13;15:1545157. doi: 10.3389/fcimb.2025.1545157. eCollection 2025.
2
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic strains.
Antimicrob Agents Chemother. 2025 May 7;69(5):e0169924. doi: 10.1128/aac.01699-24. Epub 2025 Apr 1.
3
Structural insights into alterations in the substrate spectrum of serine-β-lactamase OXA-10 from by single amino acid substitutions.
Emerg Microbes Infect. 2024 Dec;13(1):2412631. doi: 10.1080/22221751.2024.2412631. Epub 2024 Oct 22.
4
The Prevalence of Antibiotic Resistance Phenotypes and Genotypes in Multidrug-Resistant Bacterial Isolates from the Academic Hospital of Jaén, Spain.
Antibiotics (Basel). 2024 May 9;13(5):429. doi: 10.3390/antibiotics13050429.
5
Resistance in : A Narrative Review of Antibiogram Interpretation and Emerging Treatments.
Antibiotics (Basel). 2023 Nov 12;12(11):1621. doi: 10.3390/antibiotics12111621.
6
Extended-spectrum β-lactamase- producing gram-negative bacterial infections in severely ill COVID-19 patients admitted in a national referral hospital, Kenya.
Ann Clin Microbiol Antimicrob. 2023 Oct 14;22(1):91. doi: 10.1186/s12941-023-00641-8.
7
The Impact of ESBLs-Positive 's Resistance to Cefepime and Its Guidance for Clinical Treatment.
Infect Drug Resist. 2023 Sep 27;16:6395-6404. doi: 10.2147/IDR.S427836. eCollection 2023.
8
Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.
Int J Mol Sci. 2023 Apr 26;24(9):7892. doi: 10.3390/ijms24097892.
9
Knockout of Targeted Plasmid-Borne β-Lactamase Genes in an Extended-Spectrum-β-Lactamase-Producing Escherichia coli Strain: Impact on Resistance and Proteomic Profile.
Microbiol Spectr. 2023 Feb 14;11(1):e0386722. doi: 10.1128/spectrum.03867-22. Epub 2023 Jan 9.
10
Oxa-376 and Oxa-530 variants of β-lactamase: computational study uncovers potential therapeutic targets of .
RSC Adv. 2022 Aug 26;12(37):24319-24338. doi: 10.1039/d2ra02939a. eCollection 2022 Aug 22.
本文引用的文献
1
Detection of OXA-4 beta-lactamase in Pseudomonas aeruginosa isolates by genetic methods.
J Antimicrob Chemother. 1999 Feb;43(2):187-93. doi: 10.1093/jac/43.2.187.
2
beta-lactamases in Shigella flexneri isolates from Hong Kong and Shanghai and a novel OXA-1-like beta-lactamase, OXA-30.
Antimicrob Agents Chemother. 2000 Aug;44(8):2034-8. doi: 10.1128/AAC.44.8.2034-2038.2000.
3
OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain.
Antimicrob Agents Chemother. 2000 Jun;44(6):1556-61. doi: 10.1128/AAC.44.6.1556-1561.2000.
4
Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France.
Antimicrob Agents Chemother. 2000 Apr;44(4):891-7. doi: 10.1128/AAC.44.4.891-897.2000.
5
Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
Diagn Microbiol Infect Dis. 2000 Feb;36(2):125-9. doi: 10.1016/s0732-8893(99)00118-2.
6
Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel.
Antimicrob Agents Chemother. 2000 Feb;44(2):311-5. doi: 10.1128/AAC.44.2.311-315.2000.
7
Class 1 integrons, gene cassettes, mobility, and epidemiology.
Eur J Clin Microbiol Infect Dis. 1999 Nov;18(11):761-70. doi: 10.1007/s100960050398.
8
Sequence analysis of ARI-1, a novel OXA beta-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92.
Antimicrob Agents Chemother. 2000 Jan;44(1):196-9. doi: 10.1128/AAC.44.1.196-199.2000.
9
OXA-type beta-lactamases.
Curr Pharm Des. 1999 Nov;5(11):865-79.
10
Terminal truncations in amp C beta-lactamase from a clinical isolate of Pseudomonas aeruginosa.
Eur J Biochem. 1999 Jul;263(2):478-85. doi: 10.1046/j.1432-1327.1999.00529.x.
Zotero 插件